
The meta-analysis revealed that Ivabradine led to an average heart rate reduction of about 11.7 beats per minute compared to placebo treatment. This finding was consistent across different age groups, showing similar benefits in both younger and older patients. The study compiled data from 1,687 participants across 11 randomized clinical trials, with 862 patients receiving Ivabradine and 825 receiving placebo treatment.
Notably, Ivabradine works by selectively blocking specific channels in the heart’s natural pacemaker (sinoatrial node) without affecting blood pressure or heart contractility. The FDA approved Ivabradine in 2015 for treating heart failure patients with reduced ejection fraction (HFrEF) who have a heart rate above 70 beats per minute while on maximum beta-blocker therapy or in cases where beta-blockers are contraindicated. The research team used rigorous statistical methods and multiple subgroup analyses to ensure the reliability of their findings.
Source: www.cureus.com/articles/310598-effect-of-ivabradine-on-heart-failure-a-2024-meta-analysis#!/